Skip to main content
OpenTrials
Completed

NCT Number: NCT00854217

Cardioprotective Effects of Endogenous Erythropoietin in Patients Undergoing Coronary Artery Bypass Surgery

Several studies have highlighted the cardioprotective effects of acute normovolemic hemodilution during cardiac surgery. The aim of our study is to show that an increase in endogenous erythropoietin (EPO) might explain the cardioprotective effects of acute normovolemic hemodilution against ischemia-reperfusion phenomena.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiac Surgery

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cliniques Universitaires saint Luc

Brussels, 1200, Belgium

About this study

The major physiologic function of EPO is thought to be the induction of erythropoiesis. However, a growing body of evidence indicates that EPO has tissue-protective effects and prevents tissue damage during ischemia. In an ex vivo proof-of-concept, protective effects of EPO have been shown in human myocardium.

Several studies have demonstrated that acute normovolemic hemodilution before aortic cross clamping decreases perioperative myocardial damage. We hypothesized that the onset of acute anemia increases the endogenous EPO concentration, which explains the cardioprotective effects of acute normovolemic hemodilution.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients between 18 and 80 years old undergoing CABG with or without cardiopulmonary bypass

Exclusion criteria

  • emergencies
  • redo operations
  • combined surgery
  • men with Hb< 120g/dL and women with Hb< 110g/ dL
  • patients with preoperative creatinine> 2.2 mg/dL
  • poor ventricular function (EF < 50%)
  • subjects with a pulmonary disease, hepatic disease
  • subjects with carotid stenosis

Treatment and study plan

Acute Normovolemic Hemodilution

Procedure

Primary outcomes

  1. Decrease in Troponin -I values

    Time frame: 4 h

Sponsors and collaborators

Lead sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Other

Registry information

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Mar 3, 2009
Registry last updated
Mar 3, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.